Categories: News

Sopra Steria recognised as “Leader” by NelsonHall for its ability to deploy GenAI in support of organisations’ operational transformation

PARIS, Nov. 28, 2025 /PRNewswire/ — Sopra Steria, a major player in the European tech sector, has been ranked among the leaders in NelsonHall’s latest 2025 NEAT assessment for “GenAI-Enabled Operational Transformation”, particularly in the “Overall” category.

- Advertisement -

This recognition underlines the Group’s ability to industrialise GenAI to support the operational transformation of its clients, delivering fast, measurable benefits while meeting the requirements of major public- and private-sector organisations.

- Advertisement -

In this edition of the NEAT, Sopra Steria is recognised as a Leader in several key categories:

- Advertisement -
  • GenAI-Enabled Operational Transformation – Overall
  • Developing Custom GenAI Solutions
  • GenAI Support for BPS Service Delivery
  • Understanding GenAI Requirements

A robust AI strategy focused on operational impact
These results highlight the strategic direction taken by Sopra Steria to make AI a cornerstone of its offering, its operating model, and the value it delivers to its clients. Since 2023, the Group has accelerated its momentum around GenAI through:

- Advertisement -
  • The deployment of internal and external industry-specific AI solutions
  • The creation of factories to support large-scale deployment within client organisations
  • The development of an ecosystem of AI start-ups and partners
  • The structuring of new dedicated service lines

These efforts directly translate into the Group’s ability to bring robust, secure GenAI solutions into production, rapidly generating ROI for its European clients.

- Advertisement -

Yves Nicolas, Director of the Group AI Programme at Sopra Steria, said: “NelsonHall’s recognition confirms that our AI strategy has reached maturity. We have deliberately chosen an impact-driven approach: understanding the real needs of our clients, developing trustworthy GenAI solutions, and, above all, industrialising them quickly to generate operational value where it is most needed. Being ranked as leaders in so many categories reflects the commitment of our teams and our ability to harness AI to deliver concrete, measurable and lasting transformation.”

- Advertisement -

Contact
Aurélien Flaugnatti
aurelien.flaugnatti@soprasteria.com 

- Advertisement -

Logo – https://mma.prnewswire.com/media/1861938/Sopra_Steria_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/sopra-steria-recognised-as-leader-by-nelsonhall-for-its-ability-to-deploy-genai-in-support-of-organisations-operational-transformation-302627749.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

2 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

2 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

2 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

2 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

2 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

2 hours ago